Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $648.3 million.

  • Bicycle Therapeutics' Cash & Equivalents fell 2722.5% to $648.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $648.3 million, marking a year-over-year decrease of 2722.5%. This contributed to the annual value of $879.5 million for FY2024, which is 6707.48% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Cash & Equivalents of $648.3 million as of Q3 2025, which was down 2722.5% from $721.5 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Cash & Equivalents peaked at $961.4 million during Q2 2024, and registered a low of $195.9 million during Q1 2021.
  • Its 5-year average for Cash & Equivalents is $508.3 million, with a median of $438.7 million in 2021.
  • Per our database at Business Quant, Bicycle Therapeutics' Cash & Equivalents surged by 22258.25% in 2021 and then tumbled by 2788.05% in 2023.
  • Over the past 5 years, Bicycle Therapeutics' Cash & Equivalents (Quarter) stood at $438.7 million in 2021, then fell by 22.69% to $339.2 million in 2022, then surged by 55.22% to $526.4 million in 2023, then skyrocketed by 67.07% to $879.5 million in 2024, then dropped by 26.29% to $648.3 million in 2025.
  • Its last three reported values are $648.3 million in Q3 2025, $721.5 million for Q2 2025, and $793.0 million during Q1 2025.